Johnson & Johnson moves to strengthen cardiac ablation portfolio with Atraverse Medical acquisition

Johnson & Johnson has entered into a definitive agreement to acquire Atraverse Medical, signalling a focused push to expand its capabilities in cardiac electrophysiology. The deal centres on improving one of the most technically demanding steps in treating heart rhythm disorders: gaining safe and reliable access to the left atrium.

At the core of this acquisition is Atraverse’s HOTWIRE™ Transseptal Access System, an FDA-cleared solution that has already been used in nearly 3,000 clinical procedures. Designed as a radiofrequency (RF) guidewire paired with a generator, the system introduces a more controlled approach to left-heart access, an essential step in catheter ablation procedures for patients with atrial fibrillation.

A critical step, re-engineered

Accessing the left atrium has long been one of the most delicate parts of an ablation procedure. Even small inefficiencies or uncertainties at this stage can affect workflow, procedure time, and ultimately patient outcomes.

Atraverse’s HOTWIRE system addresses this with a set of practical, procedure-focused features. These include impedance-sensing technology that can automatically stop energy delivery, reducing unnecessary RF exposure, as well as improved tip visibility under intracardiac echocardiography. Compatibility with multiple sheaths also allows physicians to integrate the system more seamlessly into existing workflows.

Taken together, these elements are designed to offer electrophysiologists greater confidence and control, two factors that are especially important in complex cardiac interventions.

Strategic fit for Johnson & Johnson

For Johnson & Johnson, the acquisition represents a targeted addition rather than a broad expansion. By bringing Atraverse’s technology into its portfolio, the company is aiming to strengthen its position in cardiac ablation, an area seeing continued demand as the prevalence of atrial fibrillation rises globally.

The integration of a left-heart access system could also help streamline procedural workflows, complementing existing ablation technologies and enabling a more cohesive offering for clinicians.

Looking ahead

The transaction is expected to close in the second quarter of 2026, subject to customary conditions, with financial terms remaining undisclosed. Once completed, the acquisition will place Atraverse’s technology within a larger commercial and clinical ecosystem, potentially accelerating its adoption across electrophysiology labs.

As cardiac care continues to evolve, incremental improvements in procedural steps, such as left atrial access, are becoming increasingly important. This deal reflects a broader industry direction: refining not just the headline therapies, but the critical steps that make those therapies more effective and efficient in practice.

Source

Johnson & Johnson

Join the conversation at MedTech World North America 2026

If developments like this are on your radar, MedTech World North America 2026 is where these conversations continue. Taking place from May 11 to 13, the event will bring together key voices shaping the sector—including leadership from Atraverse Medical. John Slump, CEO, President and Co-founder, will take part in the CEO-only forum, while Dr. Steven Mickelsen, Chief Translational Science Officer and Co-founder, will join the panel “Strategic Money, Strategic Risk: What Corporate Venture Really Wants from MedTech.”

Explore the full agenda to see what’s in store and book your ticket now to avoid the last-minute rush.